Literature DB >> 7986501

Local interferon therapy for lip carcinoma.

D Ikić1, I Padovan, N Pipić, N Daković, Z Kusić.   

Abstract

In a prospective non-randomized study 21 patients with lower lip squamous cell carcinoma were treated with human natural leukocyte interferon (HNLI). The response rate was measured by a size reduction of more than 25% and was 81%. A complete response rate was considered to be a cure according to histopathological and clinical findings and was 48%. The response rate of six lower lip squamous cell carcinoma cases treated with recombinant interferon alpha 2c was 67% and the complete response rate was 17%. Three patients with basal cell carcinoma of the upper lip were also treated with HNLI. All three patients were cured, as determined by histopathological and clinical findings. These findings indicate that interferon can be a useful alternative therapy for lip carcinoma either with or without surgery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986501     DOI: 10.1007/BF00181888

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  11 in total

1.  Intralesional alpha 2b recombinant interferon for basal cell carcinomas.

Authors:  V Boneschi; L Brambilla; G Chiappino; N Mozzanica; A F Finzi
Journal:  Int J Dermatol       Date:  1991-03       Impact factor: 2.736

2.  Intralesional interferon therapy for basal cell carcinoma.

Authors:  R C Cornell; H T Greenway; S B Tucker; L Edwards; S Ashworth; J C Vance; D J Tanner; E L Taylor; K A Smiles; E A Peets
Journal:  J Am Acad Dermatol       Date:  1990-10       Impact factor: 11.527

3.  Intralesional interferon-alpha therapy in advanced malignant melanoma.

Authors:  P von Wussow; B Block; F Hartmann; H Deicher
Journal:  Cancer       Date:  1988-03-15       Impact factor: 6.860

4.  Antiviral and anti-invasive titers of human interferons.

Authors:  D Ikić; M Beck; M Juzbasić; N Delimar; V Lulić; S Smerdel; D Jusić; M Rajninger-Miholić; M Ikić
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-04

5.  The physiological interferon response.

Authors:  V Bocci
Journal:  Immunol Today       Date:  1985-01

6.  Treatment of basal cell carcinoma with intralesional interferon.

Authors:  H T Greenway; R C Cornell; D J Tanner; E Peets; G M Bordin; C Nagi
Journal:  J Am Acad Dermatol       Date:  1986-09       Impact factor: 11.527

7.  Interferon therapy for basal cell carcinoma and squamous cell carcinoma.

Authors:  D Ikić; I Padovan; N Pipić; M Knezević; N Djaković; B Rode; I Kosutić; M Belicza; V Cajkovac
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1991-09

8.  Application of human leucocyte interferon in patients with tumours of the head and neck.

Authors:  D Ikić; I Padovan; I Brodarec; M Knezević; E Soos
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

9.  Application of human leucocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma.

Authors:  D Ikić; P Nola; Z Maricić; K Smudj; V Oresić; M Knezević; B Rode; D Jusić; E Soos
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

10.  Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.

Authors:  F M Torti; L D Shortliffe; R D Williams; W C Pitts; R L Kempson; J C Ross; J Palmer; F Meyers; M Ferrari; J Hannigan
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.